Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lampalizumab for geographic atrophy secondary to age-related macular degeneration
2014-000106-35Phase 3Terminated
- Sponsor
- Roche
- Start
- Nov 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lampalizumab in age-related macular degeneration (AMD) (3 arms), sponsored by Roche. Primary endpoint: Change in geographic atrophy area. Started Nov 2014; status: terminated.
02
Drugs
lampalizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2014-000106-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000106-35.